U.S. markets closed

Timber Pharmaceuticals, Inc. (TMBR)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.8500-0.0200 (-1.07%)
At close: 4:00PM EDT

Timber Pharmaceuticals, Inc.

50 Tice Boulevard
Suite A26
Woodcliff Lake, NJ 07677
United States
973 314 9570
http://www.timberpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael Derby M.B.A., M.S.Exec. ChairmanN/AN/A1973
Mr. John Koconis M.B.A.CEO & DirectorN/AN/A1970
Mr. Zachary RomePres, COO, Exec. VP, Sec. & DirectorN/AN/A1984
Mr. Joseph LuccheseExec. VP & CFON/AN/A1967
Dr. Amir TavakkolChief Scientific OfficerN/AN/A1955
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Timber Pharmaceuticals LLC, a clinical-stage medical dermatology company, focuses on the development and commercialization of pharmaceuticals for treatment of orphan dermatologic diseases. The company was founded in 2019 and is based in Woodcliff Lake, New Jersey.

Corporate Governance

Timber Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.